title: The impact of octreotide in experimental proliferative vitreoretinopathy.
abstract: OBJECTIVE
  This study aims to investigate the effects of intravitreal octreotide on the growth factors, which have significant roles in the pathogenesis of proliferative vitreoretinopathy (PVR).
  
  
  METHODS
  An experimental trial.
  
  
  METHODS
  21 guinea pigs were randomly assigned to form 3 groups each including 7 animals. In group 1 (the control group), 0.2 ml saline solution was applied intravitreally in a location of 1.5 mm behind the limbus. In group 2 (the sham group), 0.07 IU dispase in 0.1 ml and 0.1 ml saline solution were applied via the same route. The guinea pigs in group 3 (the treatment group) were applied 0.07 IU dispase in 0.1 ml and 1 mg octreotide in 0.1 ml via the same route. Octreotide injection was applied twice during the period of 10 weeks of the experiment. At the end of the 10 weeks, eyes were enucleated and retinal homogenates were prepared. The platelet derivated growth factor (PDGF), insulin-like growth factor (IGF 1) and transforming growth factor (TGF ß) levels in homogenized retina tissue were measured by Enzyme Linked-Immuno-Sorbent Assay (ELISA) method.
  
  
  METHODS
  Kruskal-Wallis variance analysis and Mann-Whitney U test.
  
  
  RESULTS
  In the treatment group, a significant decrease was observed in retinal PDGF levels (P < 0.01) while decreases in TGF ß and IGF 1 levels were not found to be significant (P > 0.05).
  
  
  CONCLUSIONS
  Intravitreally applied octreotide at a dose of 1 mg has a highly strong effect on PDGF. This study suggests that intravitreal octreotide may suppress PVR development and that octreotide may merit investigation for PVR prophylaxis.
authors.affiliation: Department of Ophthalmology, Firat University School of Medicine, Elazig, Turkey.
authors.forename: Ozge
authors.initials: O
authors.lastname: Evren
authors.forename: Burak
authors.initials: B
authors.lastname: Turgut
authors.forename: Ulku
authors.initials: U
authors.lastname: Celiker
authors.forename: Kadir
authors.initials: K
authors.lastname: Ates
mesh_terms: D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000008:administration & dosage; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D004797:Enzyme-Linked Immunosorbent Assay; D006168:Guinea Pigs; D058449:Intravitreal Injections; D015282:Octreotide / Q000008:administration & dosage*; D012160:Retina / Q000187:drug effects / Q000378:metabolism / Q000473:pathology; D016896:Treatment Outcome; D018630:Vitreoretinopathy, Proliferative / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*
chemical_list: D018931:Antineoplastic Agents, Hormonal; D016207:Cytokines; D015282:Octreotide